ESPE Abstracts (2021) 94 FC10.4

ESPE2021 Free Communications Thyroid (6 abstracts)

Towards a novel genetic model for Congenital Hypothyroidism due to thyroid dysgenesis

Athanasia Stoupa 1,2,3 , Fabienne Jabot-Hanin 4 , Dulanjalee Kariyawasam 3 , Adrien NGuyen Quoc 2 , Sylvain Hanein 4,5 , Christine Bole-Feysot 6 , Patrick Nitschke 4 , Michel Polak 7,2,3,8,9 & Aurore Carré 7,2


1INSERM U1016, Cochin Institute, Université de Paris, Paris, France.;2IMAGINE Institute, Paris, France.;3Pediatric Endocrinology, Gynecology and Diabetology Unit, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France.;4Bioinformatics Platform, IMAGINE Institute, Université de Paris, Paris, France.;5INSERM U1163, IMAGINE Institute, Translational Genetics, Université de Paris, Paris, France.;6Genomics Platform, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France.;7INSERM U1016, Cochin Institute, Université de, Paris, France.;8Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Necker-Enfants Malades University Hospital, Paris, France.;9Centre Régional de Dépistage Néonatal (CRDN) Ile de France, Paris, France


Background: Congenital hypothyroidism (CH) affects one in 3000 children at birth. In 65% of cases, CH is due to thyroid dysgenesis (CHDT). For CHDT, there is a family component and therefore genetic. Over the past 20 years, disease-causing mutations in 10 genes have been implicated in CHDT cases (NKX2-1/TTF1, FOXE1/TTF2, NKX2-5, PAX8, GLIS3, NTN1/Netrin-1, JAG1, BOREALIN/CDCA8, TUBB1 and TSHR). In the vast majority of cases, the inheritance model is autosomal dominant. However, less than 10% of all CHDT patients have a mutation in one of these genes. Except for the 10 genes above, in our knowledge, other genes are involved in the development of the thyroid in mice, zebrafish or in vitro, which prompted us to explore genetic aspects of these genes in humans.

Aim of the study: To perform both a genetic inventory and genes interactions of all the known genes involved in the thyroid development by searching for molecular variants of these genes in a group of patients with a very well-described CHDT.

Methods: Patients were recruited through HYPOTYGEN Programme Hospitalier de Recherche Clinique (PHRC). HYPOTYGEN study is a multi-center cross-sectional clinical trial which aims to describe the population with CHDT. 482 patients with CHDT were collected and DNA samples from more than 318 CHDT patients have been sequenced through a custom-targeted NGS panel (n = 79), which were compared with 709 controls. Then, statistical analysis were performed to compare these two groups.

Results: We confirmed that patients with CHDT have a disease-causing mutation in one of the 10 known genes in 7.9% of cases. By comparing the sequencing results in the group of CHDT patients versus controls, we found variants in genes involved in the development of the thyroid, not yet involved in humans, i.e. EDN1, EYA1, CHRD, ISL1. However, the results are more complex than expected. We found, in a very interesting way, an oligogenism in the CHDT cohort as compared to the controls (P < 0.01). CHDT have a more complex origin than that described so far and the accumulation of our knowledge allows us to refine the genetic diagnosis of CHDT.

Conclusion: Beyond the monogenic model, we found an oligogenic one that explain 6,2% of the CHDT patients. The main challenge in the next years will be to enhance our understanding in the pathogenesis of CHDT by using a new paradigm, the oligogenism model on known genes.

Supported in part by a PHRC, ClinicalTrials.gov NCT01916018, Sandoz SAS, Merck

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.